LINCOLN PHARMACEUTICALS
|
The Current P/E Ratio of LINCOLN PHARMACEUTICALS is 16.24.
Share Price | ₹784.9 | Dec 26,2024 |
Market Cap | ₹1,569.8 Cr | |
Earnings-TTM | ₹96.6 Cr | TTM-Consolidated Results |
Price/Earnings | 16.24x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of LINCOLN PHARMACEUTICALS
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,569.8 Cr] as on Dec 26,2024
(/) Earnings [ ₹96.6 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 16.24x ]
Thus, for LINCOLN PHARMACEUTICALS , the investors are currently willing to pay 16.24 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of LINCOLN PHARMACEUTICALS !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of LINCOLN PHARMACEUTICALS over the last five years.
Historical PE (Price/Earnings) ratio chart of LINCOLN PHARMACEUTICALS
PE Ratio Performance Analysis for LINCOLN PHARMACEUTICALS
- LINCOLN PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2024 to Mar2020 averaged 8.66x.
- LINCOLN PHARMACEUTICALS 's operated at median p/e ratio of 8.98x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, LINCOLN PHARMACEUTICALS 's p/e ratio peaked in Mar2024 at 12.57x.
- LINCOLN PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2020 of 5.2x.
How does LINCOLN PHARMACEUTICALS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
LINCOLN PHARMACEUTICALS | 96.64 | 16.24 | 1,569.8 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 11,136.50 | 39.67 | 441,838.0 |
CIPLA LTD | 4,485.22 | 26.81 | 120,270.0 |
DR REDDYS LABORATORIES LTD | 5,406.80 | 20.91 | 113,077.0 |
ZYDUS LIFESCIENCES LTD | 4,298.90 | 22.46 | 96,553.2 |
DIVIS LABORATORIES LTD | 1,836.00 | 85.03 | 156,107.0 |
MANKIND PHARMA LTD | 2,124.86 | 56.57 | 120,212.0 |
TORRENT PHARMACEUTICALS LTD | 1,802.00 | 64.17 | 115,643.0 |
LUPIN LTD | 2,651.94 | 37.53 | 99,532.1 |
AUROBINDO PHARMA LTD | 3,598.83 | 20.27 | 72,945.8 |
ABBOTT INDIA LTD | 1,284.66 | 47.36 | 60,844.2 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs LINCOLN PHARMACEUTICALS 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 16.24x |
Max industry PE | 85.03x |
Median industry PE | 37.53x |
Average industry PE | 39.73x |
You may also like the below Video Courses